Treatments were very well tolerated with minimal acute or late side effects. Importantly, there were no cases observed of late toxicity such as pneumonitis or rib fractures;
More than 95 percent of patients and their physicians rated cosmesis -- preservation of the normal appearance of the breast -- as good/excellent at two years, the relevant timepoint for evaluation of cosmesis.
"This study builds on existing clinical evidence demonstrating the benefits of the TomoTherapy System in the treatment of breast cancer. Integrated image guidance and helical radiation delivery enables exceptional homogeneity in radiation dose delivery and superior treatments for patients. Dr. de Paula and his colleagues found that even those patients deemed cautionary or unsuitable for APBI by American Society of Radiation Oncology (ASTRO) criteria experienced a low rate of IBTR," said Fabienne Hirigoyenberry-Lanson, Ph.D., vice president global medical and scientific affairs, at Accuray.
Ad Statistics
Times Displayed: 365596
Times Visited: 7067 Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576
About the Phase II Trial
In this trial, 338 women with low-risk breast cancer received a treatment dose of 3.85 Gray (Gy) delivered by the TomoTherapy® System in 10 consecutive daily fractions, five days per week. Patients who had previously undergone breast-conserving surgery were enrolled in the study. The primary endpoints of this trial were breast tumor recurrence, and acute and late toxicity. Secondary outcomes were progression-free survival (PFS) and rates of adverse cosmesis.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide.
SOURCE Accuray Incorporated
Back to HCB News
